

Fructooligosaccharides benefits on glucose homeostasis upon high-fat diet feeding require type 2 conventional dendritic cells

Received: 8 March 2023

Accepted: 17 June 2024

Published online: 26 June 2024

 Check for updates

Adélaïde Géliéau¹, Geneviève Marcelin², Melissa Ouhachi¹, Sébastien Dussaud¹, Lise Volland², Raoul Manuel¹, Ines Baba¹, Christine Rouault², Laurent Yvan-Charvet³, Karine Clément^{2,4}, Roxane Tussiwand⁵, Thierry Huby¹ & Emmanuel L. Gautier¹✉

Diet composition impacts metabolic health and is now recognized to shape the immune system, especially in the intestinal tract. Nutritional imbalance and increased caloric intake are induced by high-fat diet (HFD) in which lipids are enriched at the expense of dietary fibers. Such nutritional challenge alters glucose homeostasis as well as intestinal immunity. Here, we observed that short-term HFD induced dysbiosis, glucose intolerance and decreased intestinal ROR γ ⁺ CD4 T cells, including peripherally-induced Tregs and IL17-producing (Th17) T cells. However, supplementation of HFD-fed male mice with the fermentable dietary fiber fructooligosaccharides (FOS) was sufficient to maintain ROR γ ⁺ CD4 T cell subsets and microbial species known to induce them, alongside having a beneficial impact on glucose tolerance. FOS-mediated normalization of Th17 cells and amelioration of glucose handling required the cDC2 dendritic cell subset in HFD-fed animals, while IL-17 neutralization limited FOS impact on glucose tolerance. Overall, we uncover a pivotal role of cDC2 in the control of the immune and metabolic effects of FOS in the context of HFD feeding.

Westernized dietary patterns have been associated to the outbreak and sharp increase in noncommunicable diseases (NCDs) over the past decades^{1,2}. Among NCDs, chronic metabolic disorders are naturally influenced by feeding habits. Indeed, while a healthy diet positively impacts host metabolism, changes in the quantity and quality of the dietary intake can favor the onset and persistence of metabolic dysfunctions³. Besides metabolism, the diet is now recognized to impact other organismal functions such as immunity, and this especially holds in the intestinal tract⁴.

Earlier studies revealed that diets low in vitamins A or aryl hydrocarbon receptor (AhR) ligands alter intestinal lymphocytes homeostasis⁵. Lately, fermentable dietary fibers have received considerable attention with regards to their widespread impact on immune cells and intestinal homeostasis⁶, adding to their well-known ability to prevent metabolic disorders⁷. Importantly, fibers are a major source of energy for the intestinal flora, and thus largely contribute to gut microbiota ecology⁸. Thus, the tightly regulated cross-talk between the gut microbiota and the host immune system is influ-

¹Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, Inserm, Research Unit on Cardiovascular and Metabolic Diseases, Hôpital de la Pitié-Salpêtrière, Paris, France. ²Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, Inserm, Nutrition and Obesity: Systemic approaches research group, NutriOmics, Paris, France. ³Institut National de la Santé et de la Recherche Médicale, Inserm, Université Côte d'Azur, Centre Méditerranéen de Médecine Moléculaire (C3M), Atip-Avenir, Fédération Hospitalo-Universitaire (FHU) Oncoage, Nice, France. ⁴Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, service de Nutrition, Paris, France. ⁵National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA. ✉e-mail: emmanuel-laurent.gautier@inserm.fr

enced by the dietary intake, which in turn shapes the metabolites, the microbiome community, and the intestinal tract immune subset composition⁹.

Unbalanced diets such as the high-fat diet (HFD) are usually low in fibers, which promotes the development of metabolic disorders^{10,11}. HFD intake induces alterations across several organs, including the intestine that contributes to systemic metabolic homeostasis by controlling glucose and lipid metabolism^{12–14}. Further, HFD-induced alteration of intestinal immune cells homeostasis concurs to precipitate metabolic dysfunctions^{15,16}. Notably, HFD feeding was shown to alter intestinal lymphocytes by hampering the maintenance of ROR γ ^t-expressing CD4⁺ T cells¹⁷. Nonetheless, the mechanisms and immune cell subsets that translate dietary cues into intestinal CD4⁺ T cells homeostasis under HFD feeding remain unexplained.

In the intestine, ROR γ ^t CD4⁺ T cells comprise two main populations. It includes regulatory T cells (Tregs) known to be induced peripherally by the microbiota (pTregs)¹⁸. These cells are involved in tolerance to the microbiota to avoid type 2 immunity¹⁹. The second population consists of IL-17-expressing T helper (Th17) cells known to be induced in response to commensals, especially segmented filamentous bacteria (SFB)²⁰. At the steady state, Th17 cells display a non-inflammatory phenotype and are involved in the regulation of the intestinal barrier^{21–23}.

Here, we report that short-term HFD (4 weeks) is sufficient to deregulate the homeostasis of Th17 cells and ROR γ ^t regulatory T cells in the intestinal tract as both subsets decreased. HFD feeding was accompanied by dysbiosis, including a reduction in microbial species known to support ROR γ ^t pTregs and Th17 cells development. Importantly, supplementation of HFD-fed animals with the fermentable dietary fiber fructooligosaccharides (FOS) prevents the loss of several of these microbial species and is sufficient to preserve both ROR γ ^t pTregs and Th17 cells in HFD-fed animals. We also reveal that FOS requires type 2 conventional CD11b⁺ dendritic cells (cDC2) to maintain intestinal Th17 cells, but not ROR γ ^t pTregs, and improve glucose homeostasis in HFD-fed animals. Finally, the impact of FOS intake on glucose tolerance was limited following IL-17 neutralization. Overall, we were able to functionally link FOS intake to the cDC2 compartment and show that this dendritic cell subset is critical to the control of the immune and metabolic effects of FOS.

Results

HFD feeding decreases ROR γ ^t pTregs and Th17 cells in the small intestine and colon

Prolonged high-fat diet (HFD) feeding was previously shown to alter the intestinal immune system^{15,16}. As the gut rapidly adapts to nutritional changes, we asked whether intestinal immune cells are impacted during the first weeks of HFD. Thus, mice were administered either HFD or regular chow diet for 4 weeks. Already at this timepoint, HFD increased body weight (Fig. 1A), weight gain (Fig. 1B), epididymal fat mass (Fig. 1C), and whole-body fat mass (Fig. 1D), but not lean mass (Fig. 1D). Furthermore, after 4 weeks of HFD, animals were glucose intolerant as circulating glucose clearance was inefficient after glucose intake during a glucose tolerance test (Fig. 1E). They also displayed an elevated HOMA-IR index (Fig. 1F), indicative of impaired glucose control by insulin. Higher HOMA-IR reflected both elevated fasting blood glucose (Fig. 1G) and insulin levels (Fig. 1H). Altogether, 4 weeks of HFD feeding altered systemic glucose homeostasis. Morphological changes in the intestinal tract were also evident in HFD-fed animals, including decreased colon weight (Fig. 1I) and length (Fig. 1J), which are commonly associated with altered colonic homeostasis. In addition, and as previously reported¹⁰, HFD feeding resulted in decreased cecum weight (Fig. 1K).

We next asked how intestinal lymphocytes were adapting to HFD and focused on ROR γ ^t CD4⁺ T cells, known to be altered under these conditions¹⁷. ROR γ ^t CD4⁺ T cells comprise IL-17-producing effector

T cells²⁴ and a population of regulatory T cells mostly induced in the periphery (pTregs)^{18,19} (Fig. 1L), both critical to maintain intestinal homeostasis^{18–20,22,25}. In chow diet-fed animals, the proportion of ROR γ ^t pTregs was similar in the mesenteric lymph nodes (mesLNs) and small intestine, but markedly higher in the colon (Fig. 1M). Th17 effector T cells were more abundant in the small intestine and colonic mucosa as compared to mesLNs, where they are generated (Fig. 1N). In HFD-fed animals, the frequency of total Tregs was unaltered in the small intestine but slightly diminished in the colon (Fig. 1O), while ROR γ ^t pTregs waned at both sites (Fig. 1P). Similarly, ROR γ ^t Th17 cells were also decreased in the small intestinal and colonic lamina propria (Fig. 1Q). Absolute cell numbers were also reduced for both ROR γ ^t pTregs and Th17 cells in the small intestine and colon (Fig. S1A). Of note, the proportion of CD4⁺ T cells, Tregs, and ROR γ ^t pTregs among CD45⁺ leukocytes decreased in both the small intestine and colon (Fig. S1B, C), while Th17 cells proportion was diminished in the small intestine only (Fig. S1C). Regarding Helios⁺ thymus-derived Tregs, their proportion was elevated in the colon while ROR γ ^t Helios⁺ double negative (DN) Tregs proportion increased in the small intestine and colon (Fig. S1D). By numbers, ROR γ ^t Tregs were reduced in the small intestine but raised in the colon (Fig. S1E), suggesting that the reduced proportion of ROR γ ^t Tregs in the colon is due to the concomitant decrease in ROR γ ^t pTregs and an increase in ROR γ ^t Tregs (Fig. S1A–E). Overall, we observed that ROR γ ^t CD4⁺ T cell subsets were reduced in the small intestine and colon after 4 weeks of HFD. Similar observations were made when mice were fed the HFD for a longer period (14 weeks) (Fig. S1F–H).

We then focused on the thymus to assess whether those alterations could come from defects in thymopoiesis. After 4 weeks of HFD, thymus weight (Fig. S1I) and cellularity (Fig. S1J) did not change. Total Tregs and thymic T cell subsets (CD4⁺ CD8 α ⁺, CD4⁺ CD8 α ⁻, CD8 α ⁺ CD4⁻) were not altered either (Fig. S1K, L). We also did not observe any alteration in splenic T cell subsets (Fig. S1M–Q). Hence, the intestinal phenotype appears independent of impairments in T cell development in the thymus.

Changes in colonic and intestinal ROR γ ^t pTregs and Th17 cells could be due to obesity itself, changes in nutrients intake or both. We thus studied genetically obese *Ob/Ob* mice maintained on a chow diet or fed with the HFD. Within the small intestine, total Tregs were slightly increased in chow-fed *Ob/Ob* mice, while ROR γ ^t pTregs and Th17 cells were similar to lean, chow-fed controls (Fig. S1R). However, and comparable to WT mice, HFD decreased the frequency of both ROR γ ^t pTregs and Th17 cells in the small intestine (Fig. S1R). In the colon, independently of the genetic background or the diet, total Tregs remained unchanged (Fig. S1S). While colonic ROR γ ^t pTregs and Th17 were significantly reduced in chow-fed obese *Ob/Ob*, HFD further decreased ROR γ ^t pTregs (Fig. S1S). The dysbiosis that has been reported in *Ob/Ob* mice²⁶ might explain why colonic Th17 cells are already impaired under CD, although we did not measure it in our study. Overall, these observations suggest that both diet and body weight impact on ROR γ ^t CD4⁺ T cells homeostasis, but that the diet has an effect per se.

Altogether, our observations reveal that 4 weeks of HFD feeding are sufficient to negatively impact on systemic glucose homeostasis and profoundly reduces ROR γ ^t pTregs and Th17 cells in the small intestine and colon.

Fermentable dietary fructooligosaccharides supplementation improves glucose tolerance and prevents ROR γ ^t pTregs and Th17 cells loss in HFD-fed animals

Next, we sought to identify the nutritional signals participating in the immune and metabolic alterations induced upon HFD feeding. In the HFD, increased fat content is achieved at the expense of cereal starches rich in dietary fibers¹⁰. Recent studies pointed out the lack of fermentable dietary fibers as a leading cause of the dysbiosis and




Fig. 1 | HFD feeding decreases ROR γ t⁺ pTregs and Th17 cells in the small intestine and colon. **A–D** Body weight ($n = 13–14$ mice per group) (**A**), body weight gain ($n = 13–14$ mice per group) (**B**), epididymal fat mass ($n = 13–14$ mice per group) (**C**) and body composition (fat and lean mass) ($n = 5–6$ mice per group, statistical significance assessed with 2-way ANOVA and Sidak's multiple comparison test, stars display adjusted P value) (**D**) in wild-type mice fed a chow diet (CD) or a high-fat diet (HFD) for 4 weeks. **E, F** Oral glucose tolerance test and associated area under the curve (AUC) quantification (**E**), HOMA-IR index measurement (**F**), fasted plasma glucose (**G**), and insulin (**H**) levels in wild-type mice fed a chow diet (CD) or a high-fat diet (HFD) for 4 weeks ($n = 13–14$ mice per group). **I–K** Colon weight ($n = 13–14$ mice per group) (**I**), colon length ($n = 9–10$ mice per group) (**J**) and caecum weight ($n = 13–14$ mice per group) (**K**) in wild-type mice fed a chow diet (CD) or a high-fat

diet (HFD) for 4 weeks. **L** Flow cytometry plots depicting ROR γ t⁺ CD4 T cells, including ROR γ t⁺ pTregs and Th17 cells, in the small intestine of chow diet-fed wild-type animals. **M, N** Flow cytometry analysis of ROR γ t⁺ pTregs (**M**) and Th17 cells (**N**) in the mesenteric lymph nodes (mesLN) ($n = 3$ mice), the small intestine ($n = 6$ mice) and the colon ($n = 5$ mice) of chow diet-fed wild-type animals. Statistical significance tested with 1-way ANOVA and Newman-Keuls multiple comparison test. **O–Q** Flow cytometry analysis of total Tregs (**O**), ROR γ t⁺ pTregs (**P**) and Th17 cells (**Q**) in the small intestine and colon of wild-type mice fed a chow diet (CD) or a high-fat diet (HFD) for 4 weeks ($n = 8–9$ mice per group). All data in this figure are presented as mean values \pm SEM. All panels correspond to two independent experimental groups. Statistical significance has been assessed with a two-sided T test unless otherwise stated on the corresponding panel legend.

metabolic alterations associated with HFD feeding^{10,11,27}. Since dietary fibers were shown to beneficially impact on immune homeostasis and the microbiota²⁸, we wondered whether their administration to HFD-fed animals would be sufficient to preserve ROR γ t⁺ pTregs and Th17

cells. In order to preserve HFD formulation, we administered fructooligosaccharides (FOS) as a fermentable fiber source in the drinking water. Under these conditions, FOS supplementation did not change body weight (Fig. 2A) nor significantly impacted body weight gain




Fig. 2 | Fructooligosaccharides supplementation improves glucose tolerance and prevents ROR γ t⁺ pTregs and Th17 cells loss in HFD-fed animals. **A–E** Body weight ($n = 15$ mice per group) (**A**), body weight gain ($n = 15$ mice per group) (**B**), epididymal fat mass ($n = 14–15$ mice per group) (**C**), and body composition (fat and lean mass) ($n = 7–10$ mice per group). Statistical significance assessed with 2-way ANOVA and Sidak's multiple comparison test, stars display adjusted P value) (**D**) and daily food intake ($n = 9$ mice per group) (**E**) in wild-type mice fed a high-fat diet (HFD) or a high-fat diet supplemented with fructooligosaccharides (FOS) (HFD + FOS) administered in the drinking water for 4 weeks. **F–J** Oral glucose tolerance test and associated area under the curve (AUC) quantification ($n = 15$ mice per group) (**F**), HOMA-IR index measurement ($n = 15$ mice per group) (**G**), plasma insulin levels ($n = 15$ mice per group) (**H**), fasted plasma glucose levels ($n = 15$ mice per group) (**I**) and glucose-stimulated insulin secretion (GSIS) ($n = 9–12$ mice per group, 2 independent experimental groups) (**J**) in wild-type mice fed a high-fat diet (HFD) or a high-fat diet supplemented with FOS (HFD + FOS) for 4 weeks. **K–M** Colon weight ($n = 13–14$ mice per group) (**K**), colon length ($n = 9–12$ mice per group) (**L**), and caecum weight ($n = 13–14$ mice per group, two independent experimental groups)

(**M**) in wild-type mice fed a high-fat diet (HFD) or a high-fat diet supplemented with FOS (HFD + FOS) for 4 weeks. **N–P** Flow cytometry analysis of total Tregs (**N**), ROR γ t⁺ pTregs (**O**), and Th17 cells (**P**) in the small intestine and colon of wild-type mice fed a high-fat diet (HFD) or a high-fat diet supplemented with FOS (HFD + FOS) for 4 weeks ($n = 13–14$ mice per group). **Q–X** Microbiome sequencing and analysis of phyla relative abundance (**Q**), Shannon index of microbial diversity (**R**), relative abundance of specific bacterial class or species including Segmented Filamentous Bacteria (SFB) (**S**), Bifidobacteria (**T**), Clostridia (**U**), *Fusobacterium nucleatum* (**V**), *Bifidobacterium breve* (**W**), and *Staphylococcus saprophyticus* (**X**) in wild-type mice fed a chow diet (CD), a high-fat diet (HFD) or a high-fat diet supplemented with FOS (HFD + FOS) for 4 weeks ($n = 4$ mice per group, each from an independent experimental group). Statistical testing with one-way ANOVA and Newman-Keuls multiple comparison test). All data in this figure are presented as mean values \pm SEM. All panels correspond to three independent experimental groups unless otherwise specified in the corresponding panel legend. Statistical significance has been assessed with a two-sided T test unless otherwise stated in the corresponding panel legend.

(Fig. 2B), epididymal fat mass (Fig. 2C), body composition (Fig. 2D), and food intake (Fig. 2E). Importantly, glucose tolerance was significantly improved by FOS supplementation (Fig. 2F). This was associated with a lowered HOMA-IR index (Fig. 2G) in FOS-treated animals that reflected decreased circulating insulin levels (Fig. 2H) rather than reduced plasma glucose concentrations (Fig. 2I). In addition, we observed that FOS increased glucose-stimulated insulin secretion (GSIS), suggesting improved pancreatic β -cell function (Fig. 2J). In summary, FOS supplementation improves systemic glucose homeostasis in HFD-fed animals.

The beneficial effect of FOS supplementation also translated into increased colon weight (Fig. 2K) and length (Fig. 2L) as well as cecum weight (Fig. 2M), reaching values similar to regular chow-fed animals (Fig. 1I–K). Beyond these morphologic parameters, FOS supplementation in HFD-fed mice did not significantly impact total Tregs in the small intestine, while it increased them in the colon (Fig. 2N). When expressed as the proportion of CD45⁺ leukocytes, CD4 T cells and total Tregs, increased in the colon but not the small intestine (Fig. S2A, B). More specifically, FOS supplementation prevented the HFD-induced drop in ROR γ ⁺ pTregs (Figs. 2O and S2A, B) and Th17 cells proportion and numbers (Figs. 2P and S2A, B) in the small intestine and colon. ROR γ ⁺ Tregs numbers were also increased (Fig. S2C). Importantly, ROR γ ⁺ pTregs and Th17 homeostasis were not affected by 4 weeks of HFD feeding nor FOS supplementation in other metabolic organs such as the liver (Fig. S3A) and the perigonadal adipose tissue (Fig. S3B). Thus, 4 weeks of HFD were not sufficient to increase Th17 cells in the adipose tissue and liver, which is known to have a detrimental impact on metabolic pathology after longer period of HFD feeding (superior to 12 weeks)^{29–33}. Hence, altered ROR γ ⁺ T cells homeostasis seems restrained to the intestine after 4 weeks of HFD.

Dietary fibers and their deprivation are capital in shaping intestinal bacterial ecology, which intricately dialogs with the immune system⁸. As ROR γ ⁺ pTregs and Th17 cells development depends on the microbiota^{18,34}, we asked whether changes in microbial ecology could explain why ROR γ ⁺ T cell subsets are altered in HFD-fed animals. As expected, the relative abundance of phyla switched towards an increase of the Firmicutes after HFD feeding (Figs. 2Q and S2D). As a consequence, microbiota diversity was drastically diminished by the HFD as measured by the Shannon index (Fig. 2R). FOS supplementation was able to partially correct, but not fully restore, Firmicutes overrepresentation and the loss of microbiota diversity (Figs. 2Q, R and S2D). Thus, HFD feeding-induced dysbiosis was partially corrected by FOS supplementation. ROR γ ⁺ pTregs and Th17 cells are induced by specific genres and taxa of the microbiota^{18,20,35,36}. SFB, the best-known Th17 inducer bacteria²⁰, was reduced upon HFD and increased following FOS supplementation (Fig. 2S). At the genre level, we assessed Bifidobacteria prevalence, which is a hallmark of fiber administration^{27,37} and has been associated with Th17 cells generation³⁵. We found that Bifidobacteria were decreased by the HFD and increased in FOS-supplemented animals (Fig. 2T). On the other hand, the most classically known inducers of ROR γ ⁺ pTregs are Clostridia strains³⁶. We observed that Clostridia were reduced in HFD-fed mice but FOS did not restore them (Fig. 2U). We also looked at specific strains previously shown to induce the generation of ROR γ ⁺ pTregs in germ-free mice¹⁸. Among them, three strains, *Fusobacterium nucleatum*, *Bifidobacterium breve* and *Staphylococcus Saprophyticus* were reduced by the HFD and significantly increased by FOS (Fig. 2V–X). Overall, we show that FOS supplementation maintains several bacterial species and genres important for the generation of ROR γ ⁺ pTregs and/or Th17 cells.

Altogether, we demonstrate that FOS supplementation in HFD-fed animals has a beneficial impact on glucose metabolism, prevents the loss of ROR γ ⁺ pTregs and Th17 cells and limits the decrease in key microbial species supporting the development of ROR γ ⁺ CD4 T cell subsets.

Th17 generation and gut-homing imprinting in the mesenteric lymph nodes are impaired by HFD feeding and corrected upon FOS supplementation

The microbiota changes presented above suggests that the decrease in ROR γ ⁺ CD4 T cells in the intestinal tract of HFD-fed mice could result from impaired priming and development in response to environmental cues. It could also be potentiated by reduced migration to the intestinal tract due to altered gut-homing imprinting. We thus focused on the mesenteric lymph nodes (mesLNs) where ROR γ ⁺ pTregs and Th17 cells are generated and educated. While total Tregs (Fig. 3A) and ROR γ ⁺ pTregs (Fig. 3B) were unaltered in the mesLNs of HFD-fed animals, Th17 cells were reduced (Fig. 3C). This revealed that Th17 cells priming was decreased upon HFD and this was associated with the drop in SFB abundance observed upon HFD feeding (Fig. 2S). We next evaluated the gut-homing imprinting of the two ROR γ ⁺ T cell subsets. The frequency of ROR γ ⁺ pTregs and Th17 cells expressing the gut-homing receptor CCR9 was reduced in HFD-fed mice (Fig. 3D, E). In addition, ROR γ ⁺ pTregs expressing the gut-homing integrin α 4 β 7 also decreased in the mesLNs upon HFD (Fig. 3D, E). Together, this indicates that the decline in intestinal Th17 cells observed after HFD feeding is owed to both decreased generation and gut-homing imprinting in the mesLNs, while ROR γ ⁺ pTregs diminution would solely rely on defective gut-homing imprinting in the mesLN.

We then sought to decipher whether the FOS supplementation would maintain ROR γ ⁺ T cells priming and gut-homing imprinting in the mesLNs of HFD-fed animals. FOS supplementation during HFD feeding increased total Tregs (Fig. 3F) as well as ROR γ ⁺ pTregs and Th17 cells (Fig. 3G) in the mesLNs. In addition, CCR9⁺ and ITG β 7⁺ ROR γ ⁺ pTregs (Fig. 3H) as well as CCR9⁺ and ITG β 7⁺ Th17 cells (Fig. 3I) were increased after FOS supplementation. To know whether this effect was specific to the HFD context, we supplemented chow diet (CD)-fed animals with FOS for 4 weeks. Total Tregs as well as ROR γ ⁺ pTregs and their gut-homing imprinting were unaltered by the FOS supplementation upon CD (Fig. S2E). Th17 cells display a tendency to increase and CCR9⁺ Th17 cells were significantly augmented (Fig. S2F). These results suggest that FOS are less efficient when administered on top of a fiber-rich CD. Thus, FOS exerts its beneficial effects when it complements the fiber-poor HFD.

FOS are fermented by the intestinal microbiota into short-chain fatty acids (SCFAs). We then asked whether FOS-mediated prevention of ROR γ ⁺ T cells alterations in HFD-fed animals was due to their fermentation into SCFAs by the microbiota. To address this point, we administered acetate, butyrate and propionate in the drinking water during the 4 weeks of HFD feeding. We observed that SCFA supplementation increased Th17 cells and their gut-homing imprinting (Fig. 3J, K) while ROR γ ⁺ pTregs were not modified (Fig. 3L, M). Thus, SCFAs were capable to limit the alterations in Th17 cells generation and education observed upon HFD feeding, but did not improve ROR γ ⁺ pTregs gut-homing imprinting.

Overall, HFD feeding decreases Th17 cells generation and gut-homing imprinting in the mesLNs, while ROR γ ⁺ pTregs only show an impairment of their gut-homing imprinting. In this context, FOS supplementation prevents the alterations observed in both ROR γ ⁺ CD4 T cell subsets.

IRF4-dependent dendritic cells (cDC2) participate in the homeostasis of ROR γ ⁺ pTregs and Th17 cells in chow-fed animals

CD103⁺ cDCs control intestinal T cells polarization in the mesLNs³⁸. This DC subset is heterogeneous and can be further subdivided into CD103⁺ CD11b⁻ cDC1 and CD103⁺ CD11b⁺ cDC2³⁹. CD103⁺ CD11b⁺ cDC2 are also found in the mesLN⁴⁰ but they remain less well characterized. While cDC1 development depends on the transcription factors BATF3 and IRF8^{41,42}, cDC2 rely on the transcription factor IRF4^{43,44} and were shown to be instrumental in the induction of intestinal Th17 cells^{43,44}. Which DC subset is responsible for the induction of intestinal ROR γ ⁺




Fig. 3 | Th17 cells generation and gut-homing imprinting of RORγt⁺ pTregs and Th17 cells are impaired by HFD feeding and corrected upon FOS supplementation. **A–C** Flow cytometry analysis of total Tregs (**A**), RORγt⁺ pTregs (**B**), and Th17 cells (**C**) in the mesenteric lymph nodes of wild-type mice fed a chow diet (CD) or a high-fat diet (HFD) for 4 weeks ($n = 8$ mice per group, 2 independent experimental groups). **D, E** Flow cytometry analysis of RORγt⁺ pTregs (**D**) and Th17 cells (**E**) expressing CCR9 or ITGβ7 in the mesenteric lymph nodes of wild-type mice fed a chow diet (CD) or a high-fat diet (HFD) for 4 weeks ($n = 7–8$ mice per group, 2 independent experimental groups). **F, G** Flow cytometry analysis of total Tregs (**F**), RORγt⁺ pTregs (**G**), and Th17 cells (**G**) in the mesenteric lymph nodes of wild-type mice fed a high-fat diet (HFD) or a high-fat diet supplemented with FOS (HFD + FOS) for 4 weeks ($n = 13–14$ mice per group, 3 independent experimental groups). **H, I** Flow cytometry analysis of CCR9 or ITGβ7-expressing RORγt⁺ pTregs (**H**) and

Th17 cells (**I**) in the mesenteric lymph nodes of wild-type mice fed a high-fat diet (HFD) or a high-fat diet supplemented with FOS (HFD + FOS) for 4 weeks ($n = 13–14$ mice per group, 3 independent experimental groups). **J, K** Flow cytometry analysis of Th17 cells (**J**) and Th17 cells expressing CCR9 or ITGβ7 (**K**) in the mesenteric lymph nodes of wild-type mice fed a high-fat diet (HFD) or a high-fat diet supplemented in SCFA (HFD + SCFA) for 4 weeks ($n = 4–6$ mice per group, 1 experimental group). **L, M** Flow cytometry analysis of RORγt⁺ pTregs (**L**) and RORγt⁺ pTregs expressing CCR9 or ITGβ7 (**M**) in the mesenteric lymph nodes of wild-type mice fed a high-fat diet (HFD) or a high-fat diet supplemented in SCFA (HFD + SCFA) for 4 weeks ($n = 4–6$ mice per group, 1 experimental group). All data in this figure are presented as mean values \pm SEM. Statistical significance has been assessed with a two-sided *T* test, stars display *P* value.

pTregs in adulthood remains, so far, less clear. Given that RORγt⁺ pTregs and Th17 cells share the expression of RORγt and are both altered upon HFD, we wondered if both subsets were primed by cDC2. In chow diet-fed *Itgax-cre x Irf4^{fllox/fllox} (Irf4^{ADC})* mice, CD103⁺ CD11b⁺ cDC2 were profoundly reduced in the intestinal lamina propria and mesLNs (Fig. S4A, B), as previously reported^{43,44}. CD103⁺ CD11b⁺ cDC2 were slightly reduced in the mesLNs (Fig. S4B) but not the lamina propria (Fig. S4A). cDC1 and macrophages were unaltered in the lamina propria (Fig. S4A) while cDC1 were slightly increased in the mesLN (Fig. S4B). We found that both Th17 cells (Fig. 4A) and RORγt⁺ pTregs (Fig. 4B) were decreased in the small intestine, colon and mesLNs of *Irf4^{ADC}* mice as compared to controls. In addition, the gut-homing imprinting of RORγt⁺ CD4 T cell subsets was decreased in *Irf4^{ADC}* mice (Fig. 4C, D). In order to assess whether cDC1 would participate in RORγt⁺ pTregs priming at the steady state, we used chow-fed *Itgax-cre x Irf8^{fllox/fllox} (Irf8^{ADC})* mice, which lack CD103⁺ CD11b⁺ cDC1 in the intestine (Fig. S5A) and mesLNs (Fig. S5B). In the small intestine, colon, and mesLNs, loss of cDC1 had no impact on RORγt⁺ pTregs (Fig. S5C) while Th17 cells were increased (Fig. S5D). Thus, cDC2, but not cDC1, participates in the maintenance of both Th17 cells and RORγt⁺ pTregs at steady state.

We then asked whether cDC subsets were affected upon HFD feeding and FOS supplementation. In HFD-fed animals, we observed a decrease in the number of CD103⁺ CD11b⁺ cDC2 in the mesLNs, while CD103⁺ CD11b⁺ cDC2 and CD103⁺ CD11b⁺ cDC1 remained unchanged (Fig. S2G). However, FOS supplementation couldn't increase cDC2 numbers in HFD-fed animals (Fig. S2H). This suggests that FOS supplementation prevented HFD-induced loss of RORγt⁺ pTregs and Th17 cells independently from the restoration of cDC2 numbers.

Gut-homing imprinting of CD4 T cells depends on retinoic acid (RA) produced by CD103⁺ cDCs in the mesLN through the action of aldehyde dehydrogenases (ALDHs) on vitamin A-derived retinol⁴⁵. HFD feeding increased ALDH activity in both cDC1 and cDC2 (Fig. S2I), while FOS supplementation decreased it (Fig. S2J). Together, these observations indicate that the HFD did not induce intrinsic cDC2 dysfunction. It rather suggests that environmental cues, such as a limited retinol bioavailability that was previously reported in HFD-fed animals⁴⁶, could impact cDCs function including their gut-homing imprinting capacities.

Collectively, we show that cDC2 are responsible for the maintenance of both RORγt⁺ CD4 T cell subsets at steady state, and that cDC2 numbers are not impacted upon FOS supplementation.

cDC2 control FOS-mediated prevention of Th17 cells loss and glucose tolerance improvement in HFD-fed animals

We showed above that cDC2 numbers are not affected by the FOS supplementation (Fig. S2H), but that cDC2 control both Th17 and RORγt⁺ pTregs at the steady state. We also showed that FOS supplementation prevented the HFD-induced decrease in microbial species known to stimulate RORγt⁺ CD4 T cells generation. Thus, we reasoned that cDC2 could control the benefits of FOS by sensing and mediating microbial-derived signals.

To test for the importance of cDC2 in mediating the benefits of FOS supplementation, we fed separated cohorts of *Irf4^{ADC}* mice and *Irf4^{fllox/fllox}* littermate controls with the HFD for 4 weeks and supplemented part of them with FOS. First, we observed that *Irf4^{ADC}* and *Irf4^{fllox/fllox}* control mice responded to FOS supplementation by increasing their colon weight and length as well as cecum weight




Fig. 4 | IRF4-dependent dendritic cells (cDC2) participate to the homeostasis of RORγt⁺ pTregs and Th17 cells. **A** Flow cytometry analysis of Th17 cells in the small intestine ($n = 9$ mice per group), colon ($n = 9$ mice per group) and mesenteric lymph nodes (mesLN) ($n = 7$ mice per group) of mice lacking *lrf4* in dendritic cells (*lrf4*^{ΔDC}) and *lrf4*^{fllox/fllox} controls (ctrl). **B** Flow cytometry plots and analysis of RORγt⁺ pTregs in the small intestine ($n = 9$ mice per group), colon ($n = 9$ mice per group) and mesenteric lymph nodes (mesLN) ($n = 7$ mice per group) of mice lacking *lrf4* in

dendritic cells (*lrf4*^{ΔDC}) and *lrf4*^{fllox/fllox} controls (Ctrl). **C, D** Flow cytometry analysis of CCR9 or ITGβ7-expressing RORγt⁺ pTregs (C) and Th17 cells (D) in the mesenteric lymph nodes of mice lacking *lrf4* in dendritic cells (*lrf4*^{ΔDC}) and *lrf4*^{fllox/fllox} controls (Ctrl) ($n = 7$ mice per group). All data in this figure are presented as mean values ± SEM. Statistical significance has been assessed with a two-sided *T* test and stars display *P* value. All panels correspond to two independent experimental groups.

(Fig. 5A–C) as reported above for wild-type animals (Fig. 2K–M). We next turned our attention to RORγt⁺ CD4 T cell subsets. Unexpectedly, RORγt⁺ pTregs were increased upon FOS supplementation in the small intestine, colon, and mesLN of mice lacking cDC2 to a comparable extent as in *lrf4*^{fllox/fllox} control animals (Fig. 5D–F). In addition, the lack of cDC2 had no impact on FOS-induced gut-homing imprinting of RORγt⁺ pTregs in the mesLN (Fig. 5G, H). This suggests that other antigen-presenting cells were capable to compensate for the lack of cDC2 in this context. Nevertheless, while FOS increased Th17 cells in the small intestine, colon and mesLN of *lrf4*^{fllox/fllox} control animals, their effect was blunted in *lrf4*^{ΔDC} mice lacking cDC2 (Fig. 5I–K). Moreover, Th17 cells gut-homing imprinting was not improved in FOS-supplemented *lrf4*^{ΔDC} mice as compared to their littermate *lrf4*^{fllox/fllox} controls (Fig. 5L, M). Thus, while FOS-mediated prevention of RORγt⁺ pTregs loss most likely benefit from cDC2-independent mechanisms, FOS impact on Th17 cells was fully dependent on cDC2. We then wondered if the absence of cDC2 had any impact on the beneficial metabolic effects of FOS supplementation in HFD-fed animals. To this aim, separated cohorts of *lrf4*^{ΔDC} mice and *lrf4*^{fllox/fllox} littermate controls were fed the HFD for 4 weeks and part of the animals were supplemented with FOS. Separated cohorts were studied as we could not perform the metabolic exploration simultaneously with such a number of animals. Body weight (Fig. 6A), weight gain (Fig. 6B), epididymal fat mass (Fig. 6C), body composition (Fig. 6D), and food intake (Fig. 6E) were not significantly modified by FOS supplementation in *lrf4*^{ΔDC} and *lrf4*^{fllox/fllox} littermate controls. Importantly, while FOS improved glucose tolerance in *lrf4*^{fllox/fllox} control animals, this effect was abrogated in *lrf4*^{ΔDC} mice lacking cDC2 (Fig. 6F), reflecting the lower HOMA-IR index (Fig. 6G) and better glucose-stimulated insulin secretion (Fig. 6H) of *lrf4*^{fllox/fllox} animals but not *lrf4*^{ΔDC} mice.

We then asked whether FOS requires an intact IL-17 signaling to improve glucose tolerance in HFD-fed mice. To answer that question, we treated HFD-fed animals supplemented with FOS with neutralizing antibodies directed against IL-17A and IL-17F, which are both produced

by Th17 cells, or their appropriate isotype control. While IL-17 neutralization did not impact on body fat mass (Fig. 6I), it limited the beneficial impact of FOS supplementation on glucose clearance (Fig. 6J). Thus, the beneficial metabolic impact of FOS partially depends on IL-17 to ameliorate glucose homeostasis, arguing that a cDC2-Th17 axis participates to the FOS-mediated improvement of metabolic fitness in HFD-fed animals.

Finally, we investigated how cDC2 could prevent HFD-induced impairments in glucose homeostasis in response to FOS. We first probed the endocrine function of the intestine. Indeed, FOS were previously reported to regulate the GLP1-GLP1R axis and the mRNA expression of proglucagon (*Gcg*, encoding the GLP-1 precursor) in the intestine to regulate glucose homeostasis in mice⁴⁷. We observed a marked trend towards decreased *Gcg* mRNA expression in the colon of HFD-fed mice, its major expression site (Fig. S6A). In addition, the HFD reduced colonic *Pyy* mRNA expression (Fig. S6A), which encodes an intestinal peptide capable to improve glucose tolerance⁴⁸. While FOS supplementation did not modulate *Gcg* expression, it increased *Pyy* levels in *lrf4*^{fllox/fllox} control mice but not in *lrf4*^{ΔDC} animals (Fig. S6B). We then assessed the effects of cDC2 depletion on the intestinal barrier upon FOS supplementation. Indeed, the barrier function of the intestine has been suggested to be instrumental in maintaining metabolic health^{49,50}. After 4 weeks of HFD, we observed a deregulation of genes encoding key antimicrobial peptides (*Reg3b* and *Reg3g*) (Fig. S6C). In addition, the mRNA levels of the genes coding for the main proteins forming the mucus layer (*Muc2* and *Muc3*) (Fig. S6D) were decreased. FOS supplementation increased *Reg3b*, *Reg3g*, *Muc2*, and *Muc3* in *lrf4*^{fllox/fllox} control mice but not in *lrf4*^{ΔDC} animals (Fig. S6E). Those results suggest that cDC2 also channels the metabolic benefits of FOS by contributing to the maintenance of the intestinal barrier function. As RegIII family lectins and mucins maintain a buffering layer between the host and the microbiota, FOS may act through a cDC2-dependent axis to restore beneficial physicochemical properties of the lumen allowing symbiosis between the microbiota and the epithelium. Along these




Fig. 5 | cDC2 control FOS-mediated prevention of Th17 cells loss in HFD-fed animals. **A–C** Colon weight (**A**), colon length (**B**), and ceacum weight (**C**) in mice lacking *Lrf4* in dendritic cells (*Lrf4*^{ΔDC}) ($n = 13–14$ mice per group) and *Lrf4*^{fllox/fllox} controls (ctrl) ($n = 11–14$ mice per group) fed a high-fat diet (HFD) or a high-fat diet supplemented with FOS (HFD + FOS) for 4 weeks. Panel **C** includes two independent experimental groups. **D–F** Flow cytometry analysis of RORγt⁺ pTregs in the small intestine (**D**), colon (**E**) and mesenteric lymph nodes (mesLN) (**F**) of mice lacking *Lrf4* in dendritic cells (*Lrf4*^{ΔDC}) ($n = 13–14$ per group) and *Lrf4*^{fllox/fllox} controls (ctrl) ($n = 11–14$ mice per group) fed a high-fat diet (HFD) or a high-fat diet supplemented with FOS (HFD + FOS) for 4 weeks. **G, H** Flow cytometry analysis of CCR9⁺ (**G**) or ITGβ7⁺ (**H**)-expressing RORγt⁺ pTregs in the mesenteric lymph nodes (mesLN) of mice lacking *Lrf4* in dendritic cells (*Lrf4*^{ΔDC}) ($n = 13–14$ mice per group) and *Lrf4*^{fllox/fllox} controls (ctrl) ($n = 14$ mice per group) fed a high-fat diet (HFD) or a

high-fat diet supplemented with FOS (HFD + FOS) for 4 weeks. **I–K** Flow cytometry analysis of Th17 cells in the small intestine (**I**), colon (**J**), and mesenteric lymph nodes (mesLN) (**K**) of mice lacking *Lrf4* in dendritic cells (*Lrf4*^{ΔDC}) ($n = 13–14$ mice per group) and *Lrf4*^{fllox/fllox} controls (ctrl) ($n = 14$ mice per group) fed a high-fat diet (HFD) or a high-fat diet supplemented with FOS (HFD + FOS) for 4 weeks. **L, M** Flow cytometry analysis of CCR9⁺ (**L**) or ITGβ7⁺ (**M**)-expressing Th17 cells in the mesenteric lymph nodes (mesLN) of mice lacking *Lrf4* in dendritic cells (*Lrf4*^{ΔDC}) ($n = 13–14$ mice per group) and *Lrf4*^{fllox/fllox} controls (ctrl) ($n = 14$ mice per group) fed a high-fat diet (HFD) or a high-fat diet supplemented with FOS (HFD + FOS) for 4 weeks. All data in this figure are presented as mean values \pm SEM. Statistical significance has been assessed with a two-sided *T* test and stars display *P* value. All panels correspond to three independent experimental groups unless otherwise stated in the corresponding panel legend.




Fig. 6 | cDC2 control FOS-mediated improvement of glucose tolerance in HFD-fed animals. A–E Body weight (**A**), body weight gain (**B**), epididymal fat mass (**C**), body composition (fat and lean mass) (**D**), and daily food intake (**E**) in mice lacking *Irf4* in dendritic cells (*Irf4*^{ΔDC}) ($n = 6–14$ mice per group) and *Irf4*^{flx/flx} controls (ctrl) ($n = 11–16$ mice per group) fed a high-fat diet (HFD) or a high-fat diet supplemented with FOS (HFD + FOS) for 4 weeks. Panels **A**, **B** and **D** include three independent experimental groups, panel **C** includes two independent experimental group. Statistical significance in panel **D** was assessed with one-way ANOVA and Sidak's multiple comparison test and stars display adjusted P value. **F–H** Oral glucose tolerance test and associated area under the curve (AUC) quantification (**F**), HOMA-IR index measurement (**G**), and glucose-stimulated insulin secretion (GSIS) (**H**) in mice lacking *Irf4* in dendritic cells (*Irf4*^{ΔDC}) ($n = 8–14$ mice per group) and *Irf4*^{flx/flx}

controls (ctrl) ($n = 12–16$ mice per group, panels **F** and **G** include three independent experimental groups, panel **H** includes two independent experimental groups) fed a high-fat diet (HFD) or a high-fat diet supplemented with FOS (HFD + FOS) for 4 weeks. **I**, **J** Body fat mass (**I**) and oral glucose tolerance test with the associated area under the curve (AUC) quantification (**J**) measured after 4 weeks of HFD in mice treated with an isotype control (HFD + IgG) as well as mice supplemented with FOS and treated with an isotype control (HFD + FOS + IgG) or antibodies neutralizing IL-17A and IL-17F (HFD + FOS + αIL-17) ($n = 6–9$ mice per group, two independent experimental groups, statistical significance tested with one-way ANOVA and Newman-Keuls multiple comparison test). All data in this figure are presented as mean values \pm SEM. Statistical significance has been assessed with a two-sided T test unless stated otherwise on the corresponding panels.

lines, previous studies showed that Th17 cells-derived cytokines regulate antimicrobial peptides production^{51–53}. In sum, we show that cDC2 are needed to mediate some positive impacts of FOS on intestinal functions known to be instrumental in glucose homeostasis. Several mechanisms likely add up in order to prevent the impairment of glucose tolerance.

Together, our work provides insight regarding the cellular mechanisms by which the fermentable dietary fiber fructooligosaccharides beneficially impact glucose metabolism. Here, we uncovered a previously unappreciated role for cDC2 in mediating these fiber's effects on Th17 cells homeostasis and systemic glucose tolerance in the context of HFD feeding.

Discussion

HFD-induced obesity remains the standard model to study obesity pathogenesis in preclinical models. HFD mimics the human “western” diet, reflecting increased fat content at the expense of dietary fibers. Such nutritional challenge leads to metabolic dysfunctions, including altered glucose homeostasis, and was shown to impact intestinal immune homeostasis. We investigated the effect of a short-term HFD regimen (4 weeks) and whether specific changes in intestinal immune subsets participate in the dysregulation of glucose homeostasis. Here, we report that HFD induces dysbiosis, including the reduction in bacterial strains known to favor RORyt⁺ CD4 T cell generation, and decreases intestinal RORyt⁺ pTregs and Th17 cells. Importantly, supplementation of HFD-fed animals with the fermentable dietary fiber fructooligosaccharides (FOS) was sufficient to prevent the drop in RORyt⁺-inducing bacterial species, maintain both RORyt⁺ CD4 T cell subsets and amend glucose homeostasis in HFD-fed animals. The beneficial effect of FOS required cDC2 to preserve Th17 cells and improve glucose tolerance. Overall, our findings unveil a previously unappreciated role of type 2 conventional dendritic cells in mediating the beneficial impact of FOS intake on mucosal immunity and glucose homeostasis in the context of HFD feeding.

RORyt⁺ pTregs and Th17 cells were decreased in the small intestine and colon of HFD-fed animals, as it was previously shown for the whole RORyt⁺ CD4 T cell pool¹⁷. This previous observation was attributed to dysbiosis¹⁷ as the gut microbiota plays a central role in the induction of RORyt⁺ expression in Th17 cells^{34,54} and peripheral Tregs^{18,19}. Recently, the HFD-mediated changes in gut microbiota ecology were shown to mostly stem from the low dietary fiber content¹¹. We reveal here that FOS intake limited the HFD-mediated reduction in the Th17-inducing bacteria SFB²⁰ and the RORyt⁺ pTreg-inducing species *B. breve* and *F. nucleatum*¹⁸. FOS supplementation also prevented the decrease of intestinal RORyt⁺ pTregs and Th17 cells in HFD-fed animals, by maintaining their priming and/or gut-homing imprinting in the mesLNs. Overall, we report that nutritional imbalance, *i.e.* dietary fiber paucity, triggers dysbiosis and impairs the maintenance of RORyt⁺ pTregs and Th17 cells. A very recent study suggests that high-sugar content can also lead to reduced SFB abundance and intestinal Th17 cells upon HFD feeding⁵⁵. This sugar-induced effect is dependent upon competition mechanisms with other members of the microbiota. Thus, different nutritional cues, such as the paucity of readily fermentable dietary fibers or an excess of sugar in the diet, favor an imbalance in microbiota species including decreased SFB abundance. The same study demonstrates that supplementing HFD with SFB improves both intestinal immunity and metabolic health upon 4 weeks of HFD, highlighting the importance of SFB decrease in our conditions.

The beneficial effect of FOS in restoring RORyt⁺ CD4 T cell subsets homeostasis likely relied on cDCs as both RORyt⁺ pTregs and Th17 cells need cDCs to develop^{19,43,44}. First, consistent with the previously described role of *Irf4*-dependent cDC2 in Th17 cell generation^{43,44}, we found that FOS-mediated preservation of Th17 cells in HFD-fed animals required cDC2. Then, we observed that cDC2, but not cDC1, participated to RORyt⁺ pTregs priming at the steady state. Yet, FOS supplementation led to the maintenance of RORyt⁺ pTregs in HFD-fed cDC2-deficient animals. Even though cDC2 have a dominant impact on RORyt⁺ pTregs at the steady state, a significant proportion of RORyt⁺ pTregs remained in their absence. This suggests that cDC1 could somewhat compensate the absence of cDC2 at the steady state and explain why RORyt⁺ pTregs were retained upon FOS supplementation in HFD-fed cDC2-deficient animals. Plasmacytoid DCs (pDCs) could also play a role in RORyt⁺ pTregs homeostasis. Indeed, both cDC1, cDC2 and pDCs are lacking in *Cd11c-cre* x *LsL-ROSA-DTA* mice⁵⁶ in which RORyt⁺ pTregs do not develop¹⁹, and pDCs were previously shown to favor RORyt⁺ pTreg generation in the intestinal tract⁵⁷. A recent study suggests that different intestinal DC subsets, including

CD103⁺ cDC1 and cDC2 as well as CD103⁺ CD11b⁺ cDCs, have the ability to induce RORyt⁺ pTregs generation depending on the context⁵⁸. Finally, other cell types such as ILC3⁵⁹ or RORyt⁺ antigen-presenting cells^{60,61} may also be involved in this compensation. In summary, while FOS intake maintains RORyt⁺ pTregs homeostasis in the absence of cDC2, Th17 cells observe a strict dependency on cDC2 to benefit from FOS supplementation.

Since FOS did not fully maintain RORyt⁺ CD4 T cells in the absence of cDC2, we tested whether cDC2 deficiency altered FOS ability to improve glucose handling. We observed that FOS failed to improve glucose tolerance in HFD-fed mice lacking cDC2. We thus identified a key role for cDC2 in mediating the beneficial metabolic effects of FOS in HFD-fed animals. This effect did not depend on RORyt⁺ pTregs but partially relied on Th17 cells since they were not restored in FOS-treated cDC2-deficient animals and IL-17 neutralization limited the full impact of FOS on glucose tolerance. On their side, RORyt⁺ pTregs might control other aspects of intestinal homeostasis given their ability to prevent Th2-driven intestinal inflammation¹⁹. Importantly, while we focused our attention on particular subsets of CD4 T cells, other alterations in immune intestinal cells have been reported upon long-term HFD feeding^{15,16}, including an increase in Th1 IFN γ -producing CD4 T cells⁶². Since intestinal Th1 responses are controlled by cDC1⁶³, further work would be needed to assess the role of cDC1 in HFD-induced metabolic alterations. Together, we show cDC2 are critical to mediate the beneficial impact of FOS on Th17 cells homeostasis and glucose homeostasis in HFD-fed animals.

Fermentable dietary fibers were previously shown to protect against HFD-induced obesity. In these studies, adding fibers to the diet markedly limited weight gain and fat mass expansion, leading to an improvement in glucose tolerance^{10,27}. Here, we delivered the fermentable dietary fiber FOS in the drinking water to keep the diet formulation similar between groups. Under our experimental conditions, FOS intake was capable to improve glucose handling independently from any major effect on adiposity. Improved glucose tolerance appeared independent from glucose absorption since blood glucose levels peaked similarly in FOS-treated animals and controls after oral glucose challenge. However, we observed that FOS supplementation accelerates glucose clearance together with improved glucose-stimulated insulin secretion. In this context, multiple mechanisms may concur to ameliorate glucose tolerance in FOS-treated animals.

In summary, the lack of fermentable dietary fiber is an important nutritional cue leading to decreased intestinal RORyt⁺ pTregs and Th17 cells in HFD-fed animals while cDC2 link FOS intake to Th17 homeostasis and the improvement of glucose tolerance. Overall, we provide insight regarding the cellular mechanisms by which fructooligosaccharides as a source of dietary fibers beneficially impact glucose metabolism. More specifically, we uncover a pivotal role of cDC2 in the control of the immune and metabolic effects of the fermentable dietary fiber fructooligosaccharides.

Methods

Mice and housing

Mice were housed in individually ventilated cages at a temperature of 22 °C and humidity of 50%, and maintained under specific pathogen-free conditions on a 12-h light and dark cycle with ad libitum access to water and diet (A04; Safe-Diets). Age-matched male mice were grouped by cages at weaning according to their genotype.

Wild-type C57BL/6J mice were from Charles River and bred in-house. *Ob/+* (*B6.Cg-Lep^{ob}/J*) mice were from Charles River and bred in house to generate obese *Ob/Ob* mice and lean littermate controls (including *Ob/+* and *+/+* animals). *Itgax-cre* (*B6.Cg-Tg(Itgax-cre)1-1Reiz/J*), *Irf4^{flox/flox}* (*B6.129S1-Irf4^{tm1Rdf}/J*) and *Irf8^{flox/flox}* (*B6(Cg)-Irf8^{tm1.1Hm}/J*) were all obtained from the Jackson Laboratory. *Itgax-cre* mice were crossed to *Irf4^{flox/flox}* animals in our facility, while *Itgax-cre* x *Irf8^{flox/flox}* were directly imported from the Tussiwand lab (Basel Institute,

Switzerland). Mice between 10 to 14 weeks of age were used, littermate cre-negative mice were used as controls and germline deletion events were screened. The presence of a deleted *Irf4* allele was identified with the following primers: *Irf4* deleted forward – ccatggtggcggatccaat and *Irf4* deleted reverse – ctctctcatctccggccttctg. This results in an approximate 120 bp band. The presence of a deleted *Irf8* allele was identified with the following primers: *Irf8* forward – caaaaaagcaggctggcgcgcg and *Irf8* deleted reverse – ccctttgaactgatggcgagctc. This results in an approximate 170 bp band.

All animal procedures were in accordance with the Guide for the Care and Use of Laboratory Animals published by the European Commission Directive 86/609/EEC and given authorization from the French Ministry of Research and local ethics committee (Charles Darwin, CEEA – 005).

Diet and treatment

For high-fat diet (HFD)-induced metabolic dysfunctions studies, male mice (10–14-week-old) were fed a HFD in which 60% of kilocalories come from fat (D12492, Research Diets) and were compared to chow diet-fed animals (A04; Safe-Lab). The duration of feeding was indicated in the text and figure legends. For dietary fiber supplementation studies, mice were given fructooligosaccharides (obtained from Sigma-Aldrich or Beneo) diluted at 7.5% in filtered drinking water. The solution was renewed every 2 to 3 days for the entire diet duration. The short-chain fatty acids acetate, propionate, and butyrate were obtained from Sigma-Aldrich and diluted in drinking water at a concentration of 60 mM, 25 mM, and 40 mM, respectively. IL-17A (clone 17F3) and IL17F (clone MM17F8F5.1A9) neutralizing antibodies, as well as their appropriate isotype control (MOPC-21), were obtained from BioXcell. Antibodies (200 µg per injection) were injected intraperitoneally 3 times a week over the 4 week period of HFD feeding.

Glucose metabolism assessment

For assessment of oral glucose tolerance, mice were fasted for 5 h prior to glucose intragastric gavage at a dose of 1.5 grams per kg of body weight. Glycaemia was measured with a glucometer (Accu-Check, Roche) at baseline and 15, 30, 60, 90, and 120 min after gavage. Blood was also collected at baseline and 15 min after gavage for insulin dosage. Insulin dosage was performed with the mouse ultrasensitive insulin ELISA kit from Alpco. The glucose-stimulation insulin secretion index was calculated as the ratio of blood insulin levels measured 15 min after glucose gavage to blood insulin levels at baseline. Finally, the HOMA-IR index was calculated with the following formula: fasting plasma insulin (mU/mL) × fasting plasma glucose (mm/L)/22.5.

Fat and lean mass measurement

Fat and lean mass were measured by TD-NMR using a MinispecPlus LFII90 body composition analyzer (Bruker; PreclinICAN Plate-form, Paris).

Tissue processing and cell suspension preparation

For isolation of lamina propria leukocytes, freshly harvested intestines and colons were quickly washed in PBS, opened, and cut into smaller pieces. To remove epithelial cells, samples were placed into 40 mL of PBS (no calcium and magnesium) containing glucose (1g/L), HEPES (10 mM), EDTA (5 mM), fetal bovine serum (5%), and dithiothreitol (0.5%), and incubated for 30 min at 37 °C under vigorous agitation. After cells were washed 5 times in 40 mL PBS, samples were chopped with scissors and placed in the digestion solution. The digestion solution consisted of HBSS (with calcium and magnesium) containing fetal bovine serum (3%), collagenase D (1.25 mg/mL, Sigma-Aldrich), DNase (10 U/mL, Sigma-Aldrich). Digestion was performed at 37 °C under agitation for 30 min. After completion, cell suspensions were passed through a 18G needle before filtration on a 70 µm filter, washed, and finally resuspended in PBS containing BSA (1%).

Liver and adipose tissue samples were directly minced into the digestion solution described above and then processed similarly to the intestines and colons.

Pooled mesenteric lymph nodes were cut open with a needle and digested as described above. Cell suspensions were eventually resuspended in PBS containing BSA (1%) before staining.

Flow cytometry

Antibodies were purchased from BioLegend, ThermoFisher Scientific, and BD Biosciences. The following markers and clones were used: CD11c (N418), MHC-II (I-A/I-E, M5/114.15.2), CD103 (2E7), CD11b (M1/70), RORγt (Q31-378), Foxp3 (FJK-16s), CD4 (GK1.5), CCR9 (CW-1.2), ITGB7 (DATK32), CD64 (X54-5/7.1) and CD45 (30-F11). Cell suspensions were stained with appropriate antibodies for 30 min on ice. Intracellular staining was performed using the Foxp3 staining kit from ThermoFisher Scientific. Aldehyde dehydrogenase (ALDH) activity was measured using the AldeRed™ ALDH Detection Assay (Merck Millipore) according to the manufacturer's instructions.

Data were acquired on a BD LSRFortessa™ flow cytometer (BD Biosciences) and analyzed with FlowJo software (Tree Star). To calculate absolute counts, a fixed number of non-fluorescent beads (10000, 10-µm polybead carboxylate microspheres from Polysciences) was added to each tube. The formula number of cells = (number of acquired cells × 10,000) / (number of acquired beads) was used. Cell counts were finally expressed as a number of cells per milligram of tissue.

Microbiome sequencing and analysis

Fecal DNA was extracted using the NucleoMag DNA Microbiome kit (Macherey-Nagel) and sequenced using the MinION from Oxford Nanopore Technologies (ONT). The DNA library was prepared with the Ligation Sequencing Kit with multiplexing (ONT). The R studio software and the Nanopore.2.0 pipeline (<https://git.ummisco.fr/ebelda/nanopore.v2.0>) were used to analyze microbiome sequencing data⁶⁴.

qPCR analysis of colon samples

Total RNA was extracted from frozen colon samples (20 mg) using the Nucleospin RNA Plus kit (Macherey-Nagel). cDNA was generated with the Transcriptor First strand cDNA Synthesis kit (Roche). Quantitative PCR was performed with SYBR Green I Master (Roche) on a LightCycler® 480 real-time PCR system with dedicated software (Roche). Gene expression was normalized to at least 2 housekeeping genes using the Roche LightCycler® 480 software.

The primers sequences are the following: *Gcg*, forward - tacacctgttcgacgtctcag and reverse - ttgaccagcattataagcaa; *Pyy*, forward - ttcgagctctcccacctt and reverse - cgagcaggattagcagcatt; *Reg3b*, forward - tggattgggtccatgac and reverse - tcatacgtcattgttactcca; *Reg3g*, forward - accatcaccatcatgtctctg and reverse - ggcatcttcttggcaact; *Muc2*, forward - acctccaggttcaaccacag and reverse - gttggccctgtgtgtgtct; *Muc3*, forward - agctgcagcgaagtggac and reverse - ccgctgtaccagtgatcc.

Quantification and statistical analysis

Statistical significance of differences was performed using GraphPad Prism (GraphPad Software). Two-tailed Student's *t* test was used to assess the statistical significance of the difference between means of two groups. When stated, one-way or two-way ANOVA followed by multiple comparison tests were conducted. Graphs depicted the mean ± SEM. Statistical significance is represented as follows: **P* < 0.05, ***P* < 0.01, ****P* < 0.001, and *****P* < 0.0001.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

Data supporting the findings described in this manuscript are available in the article, in the Supplementary Information and from the corresponding author upon request. Source data are provided with the paper. Microbiota sequencing data are available on the Sequence Read Archive (SRA) (PRJNA1099178, <https://www.ncbi.nlm.nih.gov/sra/PRJNA1099178>). Source data are provided with this paper.

References

- Ezzati, M. & Riboli, E. Behavioral and dietary risk factors for non-communicable diseases. *N. Engl. J. Med.* **369**, 954–964 (2013).
- GBD 2013 Risk Factors Collaborators et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet Lond. Engl.* **386**, 2287–2323 (2015).
- Christ, A., Lauterbach, M. & Latz, E. Western diet and the immune system: an inflammatory connection. *Immunity* **51**, 794–811 (2019).
- Thorburn, A. N., Macia, L. & Mackay, C. R. Diet, metabolites, and ‘western-lifestyle’ inflammatory diseases. *Immunity* **40**, 833–842 (2014).
- Veldhoen, M. & Brucklacher-Waldert, V. Dietary influences on intestinal immunity. *Nat. Rev. Immunol.* **12**, 696–708 (2012).
- Daïen, C. I., Pinget, G. V., Tan, J. K. & Macia, L. Detrimental impact of microbiota-accessible carbohydrate-deprived diet on gut and immune homeostasis: an overview. *Front. Immunol.* **8**, 548 (2017).
- Reynolds, A. et al. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. *Lancet Lond. Engl.* **393**, 434–445 (2019).
- Makki, K., Deehan, E. C., Walter, J. & Bäckhed, F. The impact of dietary fiber on gut microbiota in host health and disease. *Cell Host Microbe* **23**, 705–715 (2018).
- Levy, M., Thaiss, C. A. & Elinav, E. Metabolites: messengers between the microbiota and the immune system. *Genes Dev.* **30**, 1589–1597 (2016).
- Chassaing, B. et al. Lack of soluble fiber drives diet-induced adiposity in mice. *Am. J. Physiol. Gastrointest. Liver Physiol.* **309**, G528–G541 (2015).
- Dalby, M. J., Ross, A. W., Walker, A. W. & Morgan, P. J. Dietary uncoupling of gut microbiota and energy harvesting from obesity and glucose tolerance in mice. *Cell Rep.* **21**, 1521–1533 (2017).
- Drucker, D. J. The role of gut hormones in glucose homeostasis. *J. Clin. Investig.* **117**, 24–32 (2007).
- Gribble, F. M. The gut endocrine system as a coordinator of post-prandial nutrient homeostasis. *Proc. Nutr. Soc.* **71**, 456–462 (2012).
- Ko, C.-W., Qu, J., Black, D. D. & Tso, P. Regulation of intestinal lipid metabolism: current concepts and relevance to disease. *Nat. Rev. Gastroenterol. Hepatol.* **17**, 169–183 (2020).
- Winer, D. A., Luck, H., Tsai, S. & Winer, S. The intestinal immune system in obesity and insulin resistance. *Cell Metab.* **23**, 413–426 (2016).
- Winer, D. A., Winer, S., Dranse, H. J. & Lam, T. K. T. Immunologic impact of the intestine in metabolic disease. *J. Clin. Investig.* **127**, 33–42 (2017).
- Garidou, L. et al. The gut microbiota regulates intestinal CD4 T cells expressing ROR γ t and controls metabolic disease. *Cell Metab.* **22**, 100–112 (2015).
- Sefik, E. et al. MUCOSAL IMMUNOLOGY. Individual intestinal symbionts induce a distinct population of ROR γ ⁺ regulatory T cells. *Science* **349**, 993–997 (2015).
- Ohnmacht, C. et al. MUCOSAL IMMUNOLOGY. The microbiota regulates type 2 immunity through ROR γ ⁺ T cells. *Science* **349**, 989–993 (2015).
- Ivanov, I. I. et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. *Cell* **139**, 485–498 (2009).
- Omenetti, S. et al. The intestine harbors functionally distinct homeostatic tissue-resident and inflammatory Th17 cells. *Immunity* **51**, 77–89.e6 (2019).
- Chung, H. et al. Gut immune maturation depends on colonization with a host-specific microbiota. *Cell* **149**, 1578–1593 (2012).
- Lécuyer, E. et al. Segmented filamentous bacterium uses secondary and tertiary lymphoid tissues to induce gut IgA and specific T helper 17 cell responses. *Immunity* **40**, 608–620 (2014).
- Ivanov, I. I. et al. The orphan nuclear receptor ROR γ directs the differentiation program of proinflammatory IL-17+ T helper cells. *Cell* **126**, 1121–1133 (2006).
- Conti, H. R. et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. *J. Exp. Med.* **206**, 299–311 (2009).
- Ley, R. E. et al. Obesity alters gut microbial ecology. *Proc. Natl. Acad. Sci. USA.* **102**, 11070–11075 (2005).
- Zou, J. et al. Fiber-mediated nourishment of gut microbiota protects against diet-induced obesity by restoring IL-22-mediated colonic health. *Cell Host Microbe* **23**, 41–53.e4 (2018).
- Tan, J. K., McKenzie, C., Mariño, E., Macia, L. & Mackay, C. R. Metabolite-sensing G protein-coupled receptors-facilitators of diet-related immune regulation. *Annu. Rev. Immunol.* **35**, 371–402 (2017).
- MacDougall, C. E. et al. Visceral adipose tissue immune homeostasis is regulated by the crosstalk between adipocytes and dendritic cell subsets. *Cell Metab.* **27**, 588–601.e4 (2018).
- Bertola, A. et al. Identification of adipose tissue dendritic cells correlated with obesity-associated insulin-resistance and inducing Th17 responses in mice and patients. *Diabetes* **61**, 2238–2247 (2012).
- Chen, Y. et al. Adipose tissue dendritic cells enhances inflammation by prompting the generation of Th17 cells. *PLoS ONE* **9**, e92450 (2014).
- Teijeiro, A., Garrido, A., Ferre, A., Perna, C. & Djouder, N. Inhibition of the IL-17A axis in adipocytes suppresses diet-induced obesity and metabolic disorders in mice. *Nat. Metab.* **3**, 496–512 (2021).
- Zúñiga, L. A. et al. IL-17 regulates adipogenesis, glucose homeostasis, and obesity. *J. Immunol. Baltim. Md 1950* **185**, 6947–6959 (2010).
- Ivanov, I. I. et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. *Cell Host Microbe* **4**, 337–349 (2008).
- Tan, T. G. et al. Identifying species of symbiont bacteria from the human gut that, alone, can induce intestinal Th17 cells in mice. *Proc. Natl. Acad. Sci. USA.* **113**, E8141–E8150 (2016).
- Atarashi, K. et al. Induction of colonic regulatory T cells by indigenous *Clostridium* species. *Science* **331**, 337–341 (2011).
- Gibson, G. R., Beatty, E. R., Wang, X. & Cummings, J. H. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. *Gastroenterology* **108**, 975–982 (1995).
- Coombes, J. L. & Powrie, F. Dendritic cells in intestinal immune regulation. *Nat. Rev. Immunol.* **8**, 435–446 (2008).
- Merad, M., Sathe, P., Helft, J., Miller, J. & Mortha, A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. *Annu. Rev. Immunol.* **31**, 563–604 (2013).
- Cerovic, V. et al. Intestinal CD103(-) dendritic cells migrate in lymph and prime effector T cells. *Mucosal Immunol.* **6**, 104–113 (2013).
- Edelson, B. T. et al. Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8 α + conventional dendritic cells. *J. Exp. Med.* **207**, 823–836 (2010).
- Ginhoux, F. et al. The origin and development of nonlymphoid tissue CD103+ DCs. *J. Exp. Med.* **206**, 3115–3130 (2009).

43. Persson, E. K. et al. IRF4 transcription-factor-dependent CD103(+) CD11b(+) dendritic cells drive mucosal T helper 17 cell differentiation. *Immunity* **38**, 958–969 (2013).
44. Schlitzer, A. et al. IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses. *Immunity* **38**, 970–983 (2013).
45. Iwata, M. et al. Retinoic acid imprints gut-homing specificity on T cells. *Immunity* **21**, 527–538 (2004).
46. Trasino, S. E., Tang, X.-H., Jessurun, J. & Gudas, L. J. Obesity leads to tissue, but not serum vitamin A deficiency. *Sci. Rep.* **5**, 15893 (2015).
47. Delzenne, N. M., Cani, P. D. & Neyrinck, A. M. Modulation of glucagon-like peptide 1 and energy metabolism by inulin and oligofructose: experimental data. *J. Nutr.* **137**, 2547S–2551S (2007).
48. Chandarana, K. et al. Peripheral activation of the Y2-receptor promotes secretion of GLP-1 and improves glucose tolerance. *Mol. Metab.* **2**, 142–152 (2013).
49. Cani, P. D. et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. *Diabetes* **57**, 1470–1481 (2008).
50. Cani, P. D. et al. Metabolic endotoxemia initiates obesity and insulin resistance. *Diabetes* **56**, 1761–1772 (2007).
51. Liang, S. C. et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. *J. Exp. Med.* **203**, 2271–2279 (2006).
52. Zheng, Y. et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. *Nat. Med.* **14**, 282–289 (2008).
53. Ishigame, H. et al. Differential roles of interleukin-17A and -17F in host defense against mucocutaneous bacterial infection and allergic responses. *Immunity* **30**, 108–119 (2009).
54. Atarashi, K. et al. ATP drives lamina propria T(H)17 cell differentiation. *Nature* **455**, 808–812 (2008).
55. Kawano, Y. et al. Microbiota imbalance induced by dietary sugar disrupts immune-mediated protection from metabolic syndrome. *Cell* **185**, 3501–3519.e20 (2022).
56. Ohnmacht, C. et al. Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. *J. Exp. Med.* **206**, 549–559 (2009).
57. Uto, T. et al. Critical role of plasmacytoid dendritic cells in induction of oral tolerance. *J. Allergy Clin. Immunol.* **141**, 2156–2167.e9 (2018).
58. Russler-Germain, E. V. et al. Gut Helicobacter presentation by multiple dendritic cell subsets enables context-specific regulatory T cell generation. *eLife* **10**, e54792 (2021).
59. Lyu, M. et al. ILC3s select microbiota-specific regulatory T cells to establish tolerance in the gut. *Nature* **610**, 744–751 (2022).
60. Kedmi, R. et al. A RORγt+ cell instructs gut microbiota-specific Treg cell differentiation. *Nature* **610**, 737–743 (2022).
61. Akagbosu, B. et al. Novel antigen-presenting cell imparts Treg-dependent tolerance to gut microbiota. *Nature* **610**, 752–760 (2022).
62. Luck, H. et al. Regulation of obesity-related insulin resistance with gut anti-inflammatory agents. *Cell Metab.* **21**, 527–542 (2015).
63. Luda, K. M. et al. IRF8 transcription-factor-dependent classical dendritic cells are essential for intestinal T cell homeostasis. *Immunity* **44**, 860–874 (2016).
64. Alili, R. et al. Exploring semi-quantitative metagenomic studies using oxford nanopore sequencing: a computational and experimental protocol. *Genes* **12**, 1496 (2021).

Acknowledgements

This work was supported by grants to ELG from the Fondation de France (project number 00056835), the Agence Nationale pour la Recherche (ANR-17-CE14-0009, ANR-17-CE14-0023 and ANR-21-CE14-0023) and from the city of Paris (Emergence-s- program). Melissa Ouhachi received a one-year doctoral fellowship from the Nouvelle Société Française d’Athérosclérose (NSFA).

Author contributions

A.G. provided intellectual input, designed and performed experiments, analyzed and interpreted data, and wrote the manuscript. G.M. provided intellectual input, designed and performed experiments, analyzed and interpreted data, and edited the manuscript. M.O., R.M., I.B., C.R., S.D., and L.V. performed experiments and analyzed data. L.Y.C, R.T., and K.C. provided intellectual input and edited the manuscript. T.H. provided intellectual input, designed experiments, and edited the manuscript. E.L.G. conceptualized and supervised the study, designed experiments, analyzed and interpreted data, and wrote the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41467-024-49820-x>.

Correspondence and requests for materials should be addressed to Emmanuel L. Gautier.

Peer review information *Nature Communications* thanks Laurence Macia, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. A peer review file is available.

Reprints and permissions information is available at <http://www.nature.com/reprints>

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024